Bularreko Minbiziaren Cell Hazkundea gelditu Osteoporosia Droga arabera

Breast Cancer Cell Growth Halted by Osteoporosis Drug

saguak epaiketa batek erakutsi du droga denosumab dela, horiek bularreko minbizia BRCA1 genearen mutazioak dituzten emakumeak tratamendu bihurtu izan


Powered by Guardian.co.ukIzeneko artikulu hau “Bularreko minbiziaren zelula hazkuntza gelditu osteoporosia droga arabera, Azterketa ikuskizunak” zen Ian Sample Zientzia editore ek idatzitako, The Guardian astelehenean 20an ekainerako 2016 15.40 UTC

Emakumeek duten bularreko minbizia izateko arrisku handia dute dagoeneko agindutako hezur zahartzaroan galtzea tratatzeko droga bat onuragarria izango da, Australia zientzialarien arabera.

Ikertzaileak aurkitu osteoporosis droga, denosumab, can halt the growth of cells which give rise to breast tumours in women whose risk of the disease is greater because of mutations in a gene called BRCA1.

Though promising, the work is at an early stage and the results gleaned so far from lab tests on mice and breast tissue must be reproduced in large human trials before the drug can be considered as a preventative treatment.

Healthy BRCA1 and BRCA2 genes help the body repair damaged DNA. But when either gene is mutated, bularreko eta obarioko minbiziaren arriskua nabarmen igotzen. About emakumeak BRCA1 edo BRCA2 mutazio kaltegarriak bat heredatu duten bularreko minbizia garatuko ditu adinaren arabera erdia 70.

Emakumeen ezagutuko dute nork eraman kaltegarriak BRCA mutazioak aukeratzen ahal prebentzio kirurgia bere bularrak kentzeko, edo gehiago tumoreak emanaldia intentsiboa. "Ziren alternantzia aukera bat aurkitzeko interesa dugu, ez-kirurgiko emakume hauek hurbilketa bat,"Esan zuen Emma Nolan Walter eta Eliza Hall Institutuko Medical Research of Victoria at.

The scientists analysed breast tissue donated from a woman diagnosed with BRCA1 mutations. From this, they isolated a distinct group of cells that grew rapidly and appeared to be precursors of breast tumours.

Further examination of the cells revealed that they carried a protein marker on the surface, called RANK1. The same protein is targeted by denosumab, which is already used to treat osteoporosis and breast cancer which has spread to the bone.

lab probak du aldizkarian Nature Medicine, denosumab minbiziaren zelula aitzindariak, hazkundea blokeatu eta tumoreak hazkunde saguak bularreko minbizia garatzeko hazten moteldu.

"Oso hunkituta Aurkikuntza horiek gara aurkitu dugu baliagarria izan daiteke bularreko minbizia saihesteko arriskua oso altua emakumeak estrategia bat esan nahi duelako, Bereziki BRCA1 mutazio-eramaile,"Esan zuen Geoff Lindeman, Errege Melbourne Ospitaleko mediku oncologist bat. saiakuntza kliniko gaixoen droga ebaluatzeko dagoeneko hasi da, esan zuen.

Emma Smith at Cancer Research UK said: “Insights into the molecules causing tumour growth in women with faulty BRCA1 genes could lead to new treatments reducing the risk of developing breast cancer, giving these women another option to lower their risk. But this study was carried out in mice and on cells in the lab, so we don’t know how effective this approach could be at reducing breast cancer risk in women, or how it compares with options for prevention that are already available.”

guardian.co.uk © Guardian News & Media Limited 2010

Gaiarekin lotutako artikuluak